medigraphic.com
ISSN 2225-4676 (Electronic)

2014, Number 2

<< Back

Rev Cubana Neurol Neurocir 2014; 4 (2)

A guide for botulinum toxin treatment of focal dystonia, hemifacial spasm and spasticity

Betancourt NR

Language: Spanish
References: 27
Page: 192-200
PDF size: 841.17 Kb.


ABSTRACT

Objective: To elaborate a guide for the use of botulinum toxin in patients with cervical dystonia, oromandibular dystonia, blepharospasm, and hemifacial spasm assisted in specialized consultation of movement disorders.
Development: Botulinum toxin is a neurotoxic protein assembly (7 serotypes) synthesized by Clostridium botulinum. Studies have been made for use in various neurological diseases, due to its mode of action, by blocking the transmission of nerve impulses, from cholinergic neurons in neuromuscular synapses. This guide present some general considerations for the use of botulinum toxin, contraindications, adverse effects, dosages, and administration sites in cervical dystonia by type, oromandibular dystonia, blepharospasm, hemifacial spasm and spasticity.
Conclusions: Botulinum toxin has become an option for the management of many neurological entities. Nowadays is one medication for many diseases as the adult focal dystonia, and in some cases is the first choice medication.


REFERENCES

  1. Fernández RA, López–Laur JD, Cicarelli AS, de Jong LIT, Caballero PA, Bianco I. Toxina Botulínica para uso terapéutico. Rev Méd Univ Argentina 2006;2(1):1–7.

  2. Jaén Olasolo P, Fernández Lorente M. Empleo terapéutico de la toxina botulínica. Rev Clin Esp. 2005;205(3):123–6.

  3. Póo P, López–Casas J, Galván–Manso M, Aquino–Fariña L, Terricabras–Carol L, Campistol J. Toxina botulínica tipo A. Indicaciones y resultados. Rev Neurol. 2003;37(1):74– 80.

  4. Orlova OR, Timerbaeva SL, Khat'kova SE, Kotliarov VV, Korenko LA, et al. Focal dystonias and their treatment with dysport (botulinum toxin type A). Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(5):81–9.

  5. Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol. 2012 Jun; 15(3):325–36. doi: 10.1016/j.mib.2012.05.012.

  6. Burke RE, Fahn S, Marsden CD, et al. Validity and reliability of a rating scale for the primary torsion distonias. Neurology. 1985;35:73–7.

  7. Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A. Long–term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):1014–9. doi: 10.1136/jnnp–2012–303608.

  8. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15;308(1–2):103–9. doi: 10.1016/j.jns.2011.05.041.

  9. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD– 017 BoNTA Study Group. Long–term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353–60.

  10. Matic DB, Lee TY, Wells RG, Gan BS. The Effects of Botulinum Toxin Type A on Muscle Blood Per–fusion and Metabolism. Plast Rec Surg. 2007;120(7):182.

  11. Grein S, Mander GJ, Fink K. St ability of botulinum neurotoxin type A, devoid of complexing proteins. The Botulinum J. 2011;2:49–57.

  12. Tan EK, Jankovic J. Botulinum toxin A in patients with oro– mandibular dystonia. Long–term follow–up. Neurology. 1999;53:2102–7.

  13. Teive HA1, Klüppel LE, Munhoz RP, Becker N, Müller PR, Werneck LC. Jaw–opening oromandibular dystonia secondary to Wilson's disease treated with botulinum toxin type A. Arq Neuropsiquiatr. 2012 Jun;70(6):407–9.

  14. Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: Comparing different botulinum toxin preparations. Eur J Neurol 2006; 13(Suppl. 1): 21–29

  15. Andrade NN, Deshpande GS. Use of Botulinum Toxin (Botox) in the Management of Masseter Muscle Hypertrophy: A Simplified Technique. Plast Rec Surg. 2011;128(1):24e.

  16. Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010 Jun;125(6):1693–705. doi: 10.1097/PRS.0b013e3181d0ad03.

  17. Bakke M, Larsen BM, Dalager T, Møller E. Oromandibular dystonia–functional and clinical characteristics: A report on 21 cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jan;115(1):e21–6. doi: 10.1016/j.oooo.2012.04.023.

  18. Gil Polo C, Rodríguez Sanz MF, Berrocal Izquierdo N, Castrillo Sanz A, Gutiérrez Ríos R, Zamora García MI, et al. Blefarospasmo y espasmo hemifacial: tratamiento a largo plazo con toxina botulínica. Neurología. 2013;28(3):131–6. doi: 10.1016/j.nrl.2012.03.009. R. Betancourt Nápoles 200 Rev Cubana Neurol Neurocir. 2014;4(2):192–200

  19. Gill HS, Kraft SP. Long–term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can J Neurol Sci. 2010;37:631–6.

  20. Aquino CC, Felício AC, Castro PC, Oliveira RA, Silva SM, Borges V, et al. Clinical features and treatment with botulinum toxin in blepharospasm: a 17–year experience. Arq Neuropsiquiatr. 2012;70(9):662–6.

  21. Peckham EL, Lopez G, Shamim EA, Richardson SP, Sanku S, Malkani R, et al. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol. 2011 Mar;18(3):382–6. doi: 10.1111/j.1468– 1331.2010.03161.x.

  22. Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: long– term treatment with either Botox or Dysport. J Neural Transm. 2010;117:759–63.

  23. Costa J. Tratamiento con toxina Botulínica tipo A para el espasmo hemifacial. Biblioteca Cochrane Plus, número 2, 2008. Oxford, Update Software Ltd.

  24. Defazio G, Abruzzese G, Girlanda P, Vacca L, Curra A, de Salvia R, et al. Botulinum toxin. A treatment for primary hemifacial spasm: A 10–year multicenter study. Arch Neurol. 2002;59:418–20.

  25. Garreta–Figuera R, Chaler–Vilaseca J, Torrequebrada– Giménez A. Guía de práctica clínica del tratamiento de la espasticidad con toxina botulínica. Rev Neurol. 2010;50(11):685–99.

  26. Rampazo FM, Bianchin MA, Oliveira FN. Análisis comparativo de los beneficios de la ergoterapia en pacientes espásticos con afectación de las manos antes y después de la infiltración de toxina botulínica. Rev Neurol. 2009;48:459–62.

  27. Krystkowiak P, du Montcel ST, Vercueil L, Houeto JL, Lagrange C, Cornu P, et al. Reliability of the Burke–Fahn– Marsden scale in a multicenter trial for dystonia. Mov Disord. 2007 Apr 15;22(5):685–9.




2020     |     www.medigraphic.com